Article Versions Notes

Wrobel JK, Najafi S, Ayhan S, Gatzweiler C, Krunic D, Ridinger J, Milde T, Westermann F, Peterziel H, Meder B, et al. Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. Pharmaceuticals. 2020; 13(11):345. https://doi.org/10.3390/ph13110345

Wrobel, Jagoda K, Sara Najafi, Simay Ayhan, Charlotte Gatzweiler, Damir Krunic, Johannes Ridinger, Till Milde, Frank Westermann, Heike Peterziel, Benjamin Meder, and et al. 2020. "Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts" Pharmaceuticals 13, no. 11: 345. https://doi.org/10.3390/ph13110345

Wrobel, J. K., Najafi, S., Ayhan, S., Gatzweiler, C., Krunic, D., Ridinger, J., Milde, T., Westermann, F., Peterziel, H., Meder, B., Distel, M., Witt, O., & Oehme, I. (2020). Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts. Pharmaceuticals, 13(11), 345. https://doi.org/10.3390/ph13110345